Washington Trust Bancorp reported a 21% increase in net income for Q3 2026, reaching $19.4 million, up $3.4 million from the previous quarter. The growth was fueled by a 7% rise in net interest income to $44.7 million, expansion in net interest margin, and a 1.2% increase in total loans. Deposits hit a record $5.4 billion, supporting strong capital ratios and asset quality improvements. The bank declared a quarterly dividend of 56 cents per share and plans to continue leveraging its regional bank strengths for prudent growth and shareholder value.
Washington Trust Bancorp's Q3 2026 results provide context for financial sector activity on Pluang. For readers following US financial stocks, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 142 priced Financials-sector US stocks, 42 rose and 99 fell. Notable movers include OXLC at USD 7.57 with a 1-day change of -4.30%, SOFI at USD 14.45 down 4.24%, and XP at USD 30.25 up 3.47%.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
